Osiris to Present Advanced Research on Chronic Wound Treatment Using Cryopreserved Placental Membranes

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced research on cryopreserved placental membranes and their use in treating diabetic foot ulcers and other chronic wounds at the Symposium on Advanced Wound Care (SAWC), the nation’s largest interdisciplinary wound care event within the clinical field.

Multiple scientific and clinical studies will be presented, including “Unique Feature of Living Amniotic Tissue: Cell Protection from Oxidant-Induced Damage via Release of Antioxidant Mediators,” the Industrial Research and Development Poster Winner, awarded by the Wound Healing Society (WHS). This award recognizes the best product-oriented research performed by research and development scientists within the corporate world. Chronic wounds are characterized by high levels of oxidative stress, which result in cell damage and perpetuation of inflammation. Control of oxidative stress by antioxidants is necessary to restart the healing process of non-healing wounds. This study demonstrated, for the first time, that cryopreserved live human amnion, in which all components of human amnion are retained in their native state, releases low molecular weight antioxidants that protect cells from oxidant-induced damage.

Other presentations include:

• Understanding Placental Membrane Products: Impact of Commercial Preservation Methods on Anti-Inflammatory and Angiogenic Properties
• An Evidence-Based Approach to Treating Chronic Diabetic Foot Ulcers with a Human Cryopreserved Placental Membrane
• A Case Series Showing Evidence of Wound Closure Using Cryopreserved Viable Amniotic Allograft in Chronic Wounds that Failed Standard of Care Therapy
• Cellular Repair Matrix and the Management of a Diabetic Foot Ulcer, Venous Leg Ulcer, Fracture Blister and Pressure Ulcer

Osiris Therapeutics will also be exhibiting at the Symposium on Advanced Wound Care meeting at booth 741. The event runs from April 30 through May 3, 2015 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. In addition, Dr. Lawrence Lavery will host an oral presentation at the Osiris booth, entitled “A Cryopreserved, Viable Human Amniotic Membrane in Advanced Wound Care: Scientific Background and Clinical Outcomes,” on Thursday, April 30, 2015 at 7:00 p.m. and on Friday, May 1, 2015 at 1:00 p.m.

About Osiris Therapeutics

Osiris Therapeutics, Inc., based in Columbia, Maryland, is the world leader in researching, developing and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world’s first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4 ™, Cartiform® and Grafix®.

Osiris, Grafix, and Cartiform are registered trademarks of Osiris Therapeutics, Inc. BIO4 is a trademark of Stryker Corporation (NYSE: SYK). More information can be found on the company's website, www.Osiris.com. (OSIR-G)

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy biologic drug candidates and marketed Biosurgery products (including Grafix, BIO4 and Cartiform); our cash needs; patents, trademarks and other proprietary rights; the safety and ability of our products and potential products to treat disease; our ability to supply a sufficient amount of our marketed products or product candidates and, if approved or otherwise commercially available, products to meet demand; our costs to comply with governmental regulations; our plans for sales and marketing; our plans regarding facilities; types of regulatory frameworks we expect will be applicable to our products and potential products; and results of our scientific research. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled "Risk Factors" in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.